In this study, we demonstrated that drug targets for breast cancer including ER, PR, AR, and HER2 were successfully detected from the CTCs, highlighting the potential use of Hydro-Seq for precision medicine applications. This evidence concerns the gene ERBB2 and breast carcinoma.